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Purpose: Recoverin has been demonstrated to be one of the main causative antigenic retinal proteins common in many
cases of autoimmune retinopathy (AIR). Strategies for producing two different AIR mouse models associated with anti-
recoverin antibodies were tested.
Methods: (1) Six-week-old female B6.MRL-Fallpr/J mice (LPR) mice were immunized with recombinant recoverin three
times at 2–4 week intervals. (2) Five-month-old Balb/cJ mice were injected with hybridoma cells designed to produce
recoverin  monoclonal  antibodies.  Anti-recoverin  antibodies  were  analyzed  by  immunoblot  and  enzyme-linked
immunosorbent assay (ELISA). Electroretinograms (ERG), histopathologic examination, and flow cytometric analysis
were assessed.
Results: High anti-recoverin antibody levels were achieved in both models, accompanied by significantly reduced scotopic
and photopic responses on the ERGs. Retinal histology showed swollen cell bodies in the inner nuclear layer in recoverin-
immunized LPR mice, while photoreceptor and outer nuclear layer swelling was observed in recoverin hybridoma cells
injected into balb/cJ mice. Glial fibrillary acidic protein (GFAP) staining detected a marked increase of Müller cells and
astrocyte reactive gliosis in both mouse models. Rhodopsin and S-opsin staining was similar to controls, while decreased
numbers of bipolar cells were observed in both models. Complement component C1q and C3 deposits increased upon
immunohistopathologic retinal staining in both models, while increased numbers of CD4+ and CD68+ cells from retinas
were found upon flow cytometric analysis.
Conclusions: These two models had similar pathology in the retina, indicating the retinal antigens to recoverin antibody
set off pathologic events that include leukocyte invasion, complement deposition, reactive gliosis in the retina, and
selective retinal degeneration of inner nuclear layer neurons. These two AIR mouse models will allow for detailed
pathologic investigation and testing of protein antigens associated with human AIR and can be used to test treatments. It
is important to note that, since most AIR patients have multiple anti-retinal antibodies, it will be possible to study which
antibodies are pathologic and which have no retinal pathologic effects. These models can also serve as an important
research  resource  for  studying  the  pathophysiology  of  specific  retinal  proteins  by  creating  autoantibodies,  which
potentially will give a better understanding of retinal protein interactions.
Autoimmune  retinopathy  (AIR)  is  an  ophthalmologic
disease characterized by sudden and progressive loss of vision
in  association  with  circulating  anti-retinal  autoantibodies
(ARAs). The condition may occur as a primary autoimmune
condition or in association with various cancers. Three forms
have  been  reported  over  the  last  15–20  years,  including
cancer-associated retinopathy (CAR), melanoma-associated
retinopathy  (MAR),  and  non-paraneoplastic  AIR  (npAIR)
[1-3]. Complicating the understanding of AIR are cases that
have a secondary complication occurring in other disorders
such as retinitis pigmentosa or birdshot retinopathy, meaning
there can be several clinical manifestations related to anti-
retinal antibodies [4,5]. Most AIR patients do not have a
previous history of visual problems or night blindness until
they suddenly develop the onset of photopsias, followed by
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other symptoms such as night blindness, scotomata, and visual
field loss. No discernible retinal changes are initially seen
upon  fundus  examination.  However,  standardized
electroretinography (ERG) will show abnormal responses.
Many patients also have negative waveforms on dark-adapted
bright flash testing, which, along with the constellation of the
above symptoms and findings, is a hallmark of the disease
[6]. Most patients do not have pigmentary deposits, but exhibit
a diffuse hypopigmented atrophic retinopathy. Autoimmune
retinopathy typically occurs without any sign of anterior or
posterior uveitis (cells or flare upon biomicroscopy). A few
AIR cases may show retinal vascular sheathing [7,8]. While
AIR patients typically have these common clinical features,
no uniform set of ARAs have been found to be circulating in
these  patients;  typically  AIR  patients  have  three  to  six
different ARAs found on immunoblots, and the number of
bands and intensity of staining is stronger in affected patients
compared  to  normal  control  samples.  In  general,  AIR  is
treatable with immunosuppression therapies [1,9]. Currently,
most immunoreactive bands on west blot represent unknown
Molecular Vision 2010; 16:1936-1948 <http://www.molvis.org/molvis/v16/a211>
Received 9 July 2010 | Accepted 28 September 2010 | Published 2 October 2010
© 2010 Molecular Vision
1936retinal proteins. Many of the known antigenic retinal proteins
with  pathologic  associations  have  not  been  widely
investigated for lack of a good animal model system.
Autoantibodies against various retinal proteins, including
recoverin,  α-enolase,  transducin-α,  S-arrestin,  heat  shock
proteins, carbonic anhydrase II (CA II), aldolase A, aldolase
C, TULP-1, and others have been found in patients with AIR
[1,10,11].  We  identified  anti-recoverin  and  six  other
antibodies  in  several  patients  with  MAR  using  proteomic
analysis [1,10,11]. For about a decade, it was believed that
recoverin, often referred to as the CAR antigen, was the sole
autoantigen  involved  in  the  development  of  CAR.  Anti-
recoverin antibodies have been used to diagnose CAR, but
other cancer-associated antibodies have also been found [3,
10,12-14]. Patients with CAR have loss of both rods and
cones, indicating widespread retinal dysfunction [15,16].
The  protein  recoverin  is  found  in  photoreceptor  and
retinal bipolar cells and is a Ca2+-binding protein that plays a
regulatory role in phototransduction [17]. When Lewis rats
were  immunized  with  recoverin,  it  induced  uveoretinitis
[13], which is not a feature of AIR where patients do not have
cell  or  flare  clinically.  When  anti-recoverin  antibody  was
injected  intravitreally  into  anesthetized  monkey,  rat,  and
rabibit  eyes,  the  antibody  caused  retinal  cell  death  by
apoptosis in vivo [18] and in vitro [19,20].
To better understand the role of anti-recoverin antibodies
in  AIR,  we  first  tried  immunizing  C57BL/6J  mice  with
recoverin, but found minimal expression of anti-recoverin
antibody and no ERG changes. We chose B6.MRL-Faslpr/J
mice (LPR) for immunization with recoverin because upon
screening twenty mouse strains for anti-retinal antibodies it
was the only strain in which we found naturally occurring
(faint)  anti-retinal  antibodies  (data  not  shown).  B6.MRL-
Faslpr/J  mice  have  a  lymphoproliferation  spontaneous
mutation (Faslpr) that show systemic autoimmunity and are
regarded as a mouse model for lupus [21]. We chose this strain
to  investigate  if  an  AIR  model  could  be  induced  by
immunization  with  recoverin.  A  second  approach  in  our
search for murine models of AIR was to create recoverin-
sensitized hybridoma cells and then to implant the hybridoma
cells in balb/cJ mice. This approach allowed us to examine if
high  levels  of  circulating  anti-recoverin  antibody  would
produce a retinopathy.
METHODS
Animals: All studies involving mice were approved by the
University Committee on the Use and Care of Animals at the
University  of  Michigan.  B6.MRL-Faslpr/J  (LPR)  mice,
C57BL/6J mice, and balb/cJ mice were obtained from Jackson
Laboratory, Bar Harbor, ME. Sample sizes of six for each
group were chosen due to the scarcity of recoverin protein for
immunization.
Purification of recombinant recoverin: A mouse recoverin-
expressing  construct  was  made  in  pET11a-Rec  (kindly
provided by Dr. James Hurley). Recombinant recoverin was
purified as described previously [22]. Briefly, a recoverin
construct was transformed and expressed in E. coli strain
BL21 (DE3) pLysS (Novagen, Merck, Darmstadt, Germany).
The  culture  was  grown  in  250  ml  of  LB  (Luria–Bertani)
medium at 37 °C containing ampicillin (50 μg/ml). Protein
expression  was  induced  with  1  mM  isopropyl  α-d-
thiogalactopyranoside  and  cells  were  incubated  for  an
additional 3 h at room temperature. Cells were then harvested
by  centrifugation  and  re-suspended  in  10  ml  of  buffer  A
(50 mM Hepes (pH 7.5), 100 mM NaCl, 1 mM CaCl2, 5 mM
α-mercaptoethanol, and 0.1 mM PMSF). After sonication and
centrifugation (20,000× g for 30 min at 4 °C), the cleared
lysate  was  loaded  onto  a  buffer  A-preequilibrated  Econ-
column (10 mm id×10 cm; Bio-Rad, Hercules, CA) with 5 ml
of Phenyl Sepharose 6 Fast Flow (low sub resin; Amersham
Biosciences, GE healthcare, Piscataway, NJ) at a flow rate of
0.4 m/min. The column was washed (2 ml/min) with at least
10 column volumes of buffer A to remove nonspecifically
adsorbed proteins. Fractions of purified recoverin were eluted
(0.4 ml/min) with buffer B (5 mM Hepes pH 7.5, 100 mM
NaCl, 5 mM α-mercaptoethanol, and 5 mM EGTA) and stored
at −70 °C until use.
Hybridoma cell generation: Six-week-old balb/cJ mice were
used  for  hybridoma  production.  In  brief,  50  μg  recoverin
protein in 200 µl of PBS or 200 µl of PBS (for control mice)
were  mixed  with  equal  volumes  of  Complete  Freund's
adjuvant (Pierce, Rockford, IL). The mixed emulsion was
injected intraperitoneally on day 0; a second dose of 50 µg
recoverin protein in an emulsion with Incomplete Freund's
adjuvant (Pierce) was injected intraperitoneally on days 14
and 42. When the serum antibody titer reached twice the
background value at 1:10,000 dilution, single spleen cells
from  the  immunized  mice  were  fused  with  previously
prepared myeloma cells [23]. Fusion is accomplished by co-
centrifuging freshly harvested spleen and myeloma cells in
the  presence  of  polyethylene  glycol.  The  cells  were  then
distributed  to  96-well  plates  containing  feeder  cells.  The
newly formed small clusters of hybridoma cells from the 96-
well plates were then grown in tissue culture flasks and clone
screening was performed to determine which cultures were
producing recoverin antibodies.
Mouse model: Six-week-old LPR mice or C57BL/6J mice
were injected intraperitoneally with 50 µg recoverin (n=6) or
PBS  (n=6;  control  mice)  in  an  emulsion  with  Complete
Freund's  adjuvant  containing  Mycobacterium  tuberculosis
(1:1, v/v; Pierce) on day 0; 50 µg protein in an emulsion with
Incomplete Freund's adjuvant (1:1, v/v; Pierce) were injected
intraperitoneally on days 14 and 42. On day 49, tail blood was
taken using capillary tubes (Sarstedt, Numbrecht, Germany),
ERGs were recorded, and the mouse eyes were enucleated
after euthanasia (ketamine [80 mg/kg] and xylazine [16 mg/
kg])  for  histopathologic  examination  and  flow  cytometric
analysis.
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1937Hybridoma model: Five-month-old balb/cJ mice were given
pristane  (500  μl)  two  weeks  before  the  intraperitoneal
injection  of  hybridoma  cells  (5×106  cells;  n=6).  Ascites
formed 7–10 days after the injection and were withdrawn for
antibody testing. Next, ERGs were recorded and the mice eyes
were taken as above for histology.
Electroretinography: Mice were dark-adapted overnight and
anesthetized with an intraperitoneal injection of normal saline
solution containing ketamine (80 mg/kg) and xylazine (16 mg/
kg). Next, ERGs were recorded from the corneal surface after
pupil dilation (0.1% atropine and 0.1% phenylephrine HCl)
using a gold loop electrode referenced to a gold wire in the
mouth. An electrode placed in the tail served as a ground. A
drop of methylcellulose (2.5%) was placed on the corneal
surface to ensure electrical contact and to maintain corneal
integrity.  Body  temperature  was  maintained  at  a  constant
temperature of 38 °C using a heated water pad. All stimuli
were  presented  in  a  Ganzfeld  dome  (LKC  Technologies,
Gaithersburg,  MD).  Rod-dominated  responses  to  white
flashes of light over a 4.0–5.0 log unit range of intensities were
recorded.  Cone-dominated  responses  were  obtained  with
white flashes over a 2.0 log unit range of intensities at 2.1 Hz
on a rod-saturating background (1.46 log cd/m2) after 10 min
of exposure to the background light to allow for complete light
adaptation.  Responses  were  amplified  and  filtered  (0.03–
10,000 Hz) and digitized using an I/O board (model PCI-1200;
National Instruments, Austin, TX) in a personal computer.
Evoked responses were sampled every 0.5 ms over a response
window of 240 ms. For each stimulus condition, responses
were computer-averaged with up to 20 records averaged for
the weakest signals.
Immunoblot analysis: Purified recoverin (0.2 µg) was applied
to  4%–20%  linear  gradient  Tris–HCl  gel  (Bio-Rad)  and
transferred onto nitrocellulose membranes (Bio-Rrad). The
membranes were blocked with 5% milk and incubated with
samples of analyzed sera diluted 1:1,000. Immune complexes
were  detected  with  anti-mouse  IgG  goat  horseradish
peroxidase-conjugated  secondary  antibodies
(SouthernBiotech,  Birmingham,  AL)  and  enhanced  with
chemiluminescent substrate (Pierce).
ELISA for serum antibodies to recoverin: Serum antibodies
to  recoverin  were  quantified  by  enzyme-linked
immunosorbent  assay  (ELISA).  Briefly,  microtiter  plates
were coated with 100 ng/well of recoverin in 0.1 M Tris-HCl
buffer, pH 9.0, overnight at room temperature. Following five
washes with phosphate buffer solution (PBS), the plates were
coated with 1% skim milk in PBS for 2 h at room temperature
and then were incubated with 50 μl of diluted serum in PBS
for 2 h at room temperature. After five washes with PBS
containing 0.05% Tween-20, the plates were incubated with
50  µl  of  goat  anti-human  IgG  antibody  conjugated  with
horseradish  peroxidase  (SouthernBiotech)  at  room
temperature  for  2  h.  Following  five  washes  with  PBS
containing 0.05% Tween-20, bound reactants were developed
with 50 µl of 50 µg/ml 2,2'-azinobis diammonium salt (Pierce)
in citrate-phosphate buffer (pH 4.0; 0.2M Na2HPO4, 0.1M
citrate,  1.0  ìl/10  ml  of  30%  H2O2).  The  absorbance  was
determined at 405 nm.
Light  microscopy:  Eyes  were  immediately  removed  and
immersed in a cold fixative of 4% glutaraldehyde in 0.1 M
phosphate buffer. Corneas were removed and the eyes left in
fixative for 24 h. The lens was then removed, followed by
dehydration  with  a  graded  series  of  increasing  ethanol
concentrations. Eyecups were embedded in an Epon mixture.
For  each  sample,  0.5  µm-thin  sections  were  stained  with
toluidine blue for light microscopy.
Immunohistochemistry: Frozen sections were obtained from
retina  embedded  in  Optimal  Cutting  Temperature  (OCT;
Tissue-Tek; Miles Inc., Elkhart, IN). Sections were blocked
for non-specific protein-binding with 3% BSA in PBS at room
temperature for 1 h and then incubated with the first antibody
for 2 h at room temperature in PBS containing 3% BSA. After
washing with PBS+0.2% Triton X-100 (room temperature,
3×10 min), the sections were incubated with the fluorescence-
conjugated secondary antibody in PBS+3% BSA. They were
then  counterstained  with  4',6-diamidino-2-phenylindole
(DAPI;  0.3  µM)  before  observation  with  a  fluorescence
microscope (Olympus, Tokyo, Japan). The anti-glial fibrillary
acidic protein (GFAP) antibody (1:500 dilution) was from
Abcam  (Cambridge,  MA),  the  anti-rhodopsin  (1:500
dilution), anti-S-opsin, and anti-calretinin antibodies (1:500
dilution) were from Millipore (Billerica, MA), the anti PKC-
α antibody was from Sigma (St. Louis, MO), and the anti-C1q
and anti-C3 antibodies (1:500 dilution) were from Cederlane
(Burlington, NC).
Flow cytometry: White blood cells and macrophages were
obtained  from  control  and  AIR  mice  retinas  by  vigorous
pipetting and were centrifuged. Staining for flow cytometry
was performed within 24 h. Briefly, fluorochrome-conjugated
mAbs were added to cells (1 µg/106 cells). These were then
incubated in the dark for 20 min at room temperature. Cells
were  washed  twice  with  staining  buffer,  resuspended  in
Cytofix (BD Biosciences, San Jose, CA), and kept in the dark
at 4 °C until cytometric analysis (within 24 h). Analysis was
performed  on  a  FACSCalibur  flow  cytometer  (BD
Biosciences).  Mean  fluorescent  intensity  (MFI)  was
calculated as a ratio of mean fluorescence sample/isotype
fluorescence. Percentage positive expression was calculated
by  comparing  the  population  of  cells  with  increased
fluorescent intensity to the following isotypes: anti-CD4, -
CD8, -CD19, -CD69; anti-Ly6G antibodies were from BD
Biosciences  and  the  anti-mouse  CD68  antibody  (1:500
dilution) was from Fisher Scientific (Pittsburgh, PA).
Statistical analysis: The student t-test was employed for the
statistical  analysis.  Statistical  significance  was  defined  as
p<0.05. All data were presented as mean±SD.
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1938RESULTS
Purification  of  recombinant  recoverin  and  generation  of
recoverin hybridoma cells: We first purified the recombinant
recoverin using a Phenyl Sepharose 6 Fast Flow column. The
purity of recoverin was confirmed by SDS–PAGE analyses of
the  supernatant  during  the  recoverin  purification  process
(Figure  1A)  and  the  purified  recombinant  recoverin  was
confirmed by immunoblotting (Figure 1B). We also generated
recoverin monoclonal antibody-producing hybridoma cells
and then injected the cells intraperitoneally in five-month old
balb/cJ mice. Ascites formed after about 10 days [23] and the
ascitic fluid was withdrawn to test the recoverin antibody level
(Figure 1C).
Recoverin-associated  retinopathy  mouse  models:  To  test
whether  pathologic  retinopathy  could  be  generated  by
immunizing  recoverin  in-C57BL/6J  mice  and  B6.MRL-
Faslpr/J  (LPR)  mice,  we  initially  challenged  six-week-old
mice with 50 µg recoverin intraperitoneally and repeated this
two more times over eight weeks, at which time the antibody
levels  were  tested.  Anti-recoverin  antibody  levels  were
significantly  increased  in  recoverin-immunized  LPR  mice
compared to control LPR mice (p<0.05), while the antibody
titer was ~2 times higher in recoverin-sensitized LPR mice
compared to recoverin-sensitized C57BL/6J mice (Figure 2).
Similar results were found in the immunoblotting analysis
(Figure 2). These data indicate higher anti-recoverin antibody
levels can be achieved in LPR mice than in C57BL/6J mice
using the same methodology. Electroretinogram recordings
were used to determine whether immunization with recoverin
affects  the  retinal  function  in  C57BL/6J  and  LPR  mice.
However, small but significant electroretinographic changes
(p<0.05)  in  recoverin-immunized  C57BL/6J  mice  were
observed in the scotopic, photopic, and maximum responses
compared to control C57BL/6J mice (Figure 2). However,
degeneration was not detected upon histology and the ERG
changes in the immunized C57BL/6J mice revealed a small
physiologic effect of the autoantibodies. By comparison, the
histologic  changes  in  the  LPR  mice  suggest  that  higher
elevations of anti-recoverin antibodies are needed to elicit
disease.  However,  the  ERG  amplitudes  of  recoverin-
immunized mice for the scotopic, photopic, and maximum
electroretinographic responses were significantly reduced by
~35% compared with control LPR mice (Figure 2, Figure 3;
inset table in Figure 3).
Figure  1.  Purification  of  recombinant
recoverin and generation of recoverin
hybridoma  cells.  A:  Sodium  dodecyl
sulfate PAGE (SDS–PAGE) analysis of
the  fractions  during  the  recoverin
purification process. 1) crude extract; 2)
after centrifugation; 3) after filtration; 4
and 5) apply to column; 6) wash column;
7–11) elution. B: Immunoblot analysis
of the eluted fractions of recoverin. C:
Immunoblot analysis of the ascites from
three  balb/cJ  mice  injected  with
recoverin  hybridoma  cells.  Molecular
size standards are shown on the left.
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1939We  also  injected  the  recoverin  hybridoma  cells
intraperitoneally  in  five-month  old  balb/cJ  mice.  Ascites
formed after about 10 days and the ascitic fluid was withdrawn
to test the recoverin antibody level (Figure 1C); the ERG was
also  tested.  Both  b-  and  a-wave  amplitudes  in  scotopic
electroretinographic responses were reduced by about 50% in
mice who received sham intraperitoneal injections compared
to  control  balb/cJ  mice;  b-wave  amplitudes  in  photopic
electroretinographic responses were reduced by ~40% (Figure
3).
Retinal changes in recoverin-associated retinopathy mouse
models: After LPR mice were sensitized with recoverin three
times,  we  evaluated  the  mouse  eyes  using  biomicroscopy
(25×) and indirect retinoscopy; there were no cells in the
aqueous or vitreous, which excluded active uveitis. The eyes
were then enucleated for histopathologic analysis two weeks
after the last immunization. In the recoverin-sensitized LPR
mice, H&E staining showed cell body swelling throughout the
inner nuclear layer (INL) and migrating cells between the INL
and ganglion cell layer (GCL) were also observed (Figure 4).
In LPR-sensitized mice, GFAP staining demonstrated
Mueller and astrocyte swelling and increased numbers in
the INL and GCL compared to normal controls (Figure 5;
GFAP). Rhodopsin and S-opsin expression were not altered
in either group, while bipolar cells (stained with protein kinase
C-α  antibodies)  were  decreased  in  recoverin-immunized
LPR mice (Figure 5). Although amacrine cells showed no
change, the interplexiform layer (IPL) was thinned compared
to controls.
H&E  staining  from  hybridoma-injected  balb/cJ  mice
showed  photoreceptor  and  outer  nuclear  layer  (ONL)
thickening that was uneven in distribution (Figure 4), as well
as migrating cells between the INL and GCL. Glial fibrillary
acidic  protein  staining  showed  a  remarkable  increase  in
astrocyte and glial staining from the INL to the GCL (Figure
5). Rhodopsin and S-opsin expression were not altered in
either group, while bipolar cells (PKC-α) were decreased in
the hybridoma-injected balb/cJ mice. Amacrine cells were not
changed, but the IPL was noticeably thinned. (Figure 5)
The  complement  system  is  known  to  participate  in  a
variety of ocular diseases, including macular degeneration and
uveitis  [24,25].  Complement  components  contribute  to
pathogenic processes by damaging the tissue and stimulating
chemotaxis and in age-related macular degeneration (AMD)
are known to facilitate neovascularization. C1q is able to
directly bind to apoptotic cells via its globular head domains,
which may induce complement activation with subsequent
opsonization of C4b and C3b to the surface of apoptotic cells
Figure  2.  Accelerated  anti-recoverin
antibodies  in  recoverin-immunized
B6.MRL-Faslpr/J (LPR) mice associated
with  attenuated  electroretinogram
(ERG) responses. Although there was
an increase of anti-recoverin antibodies
in  recoverin-immunized  C57BL/6J
mice,  the  ERG  responses  were  still
normal compared with control C57BL/
6J  mice.  The  antibody  level  was
significantly  enhanced  in  recoverin-
immunized  LPR  mice  compared  with
recoverin-immunized C57BL/6J mice,
accompanied by attenuated scotopic and
photopic ERG responses. A serum titer
(1:10,000  dilution)  of  anti-recoverin
antibodies  was  analyzed  by  enzyme-
linked  immunosorbent  assay  (ELISA;
upper) and western blot (middle); ERG
responses were also analyzed (bottom).
There  were  significant  differences  in
antibody levels by ELISA in recoverin-
immunized  LPR  mice  versus  control
LPR  mice  (p<0.001);  recoverin-
immunized LPR mice versus recoverin-
immunized C57BL/6J mice (p<0.001);
recoverin-immunized  C57BL/6J  mice
versus control C57BL/6J mice (p<0.05).
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1940[26]. To test if complement components were involved in the
mechanism  of  our  two  recoverin-associated  AIR  mouse
models, we stained for C1q and C3.
Immunohistochemical analyses showed that compared
with control LPR mice, scattered C1q deposits were observed
in the retinal pigment epithelium (RPE), INL, and GCL of
recoverin-immunized LPR mice (Figure 6). No sections of the
control LPR mice exhibited C1q deposits in the retina (Figure
6). Although there were C3 deposits in the RPE of control
LPR mice (Figure 6), C3 deposits were remarkably increased
in  the  RPE  layer  in  recoverin-immunized  LPR  mice  and
scattered C3 deposits were found in the INL and GCL (Figure
6). CD3+ cells were observed between the INL and GCL
layers, and the migrating cells between INL and GCL were
CD3+ cells (Figure 6). CD68+ cells were found in the IPL and
OPL in recoverin-immunized LPR mice retina (Figure 6).
Immunohistologic  microscopy  showed  that  compared
with control balb/cJ mice, very few scattered C1q deposits
were  found  in  the  RPE,  INL,  and  GCL  of  recoverin
monoclonal antibody-producing hybridoma cells injected in
the  balb/cJ  mice  (Figure  6).  There  was  no  C1q
immunostaining in control balb/cJ mice. The staining for C3
Figure 3. Attenuated electroretinogram
(ERG)  response  in  recoverin-
immunized  B6.MRL-Fallpr/J  mice
(LPR) mice and balb/cJ mice injected
with  recoverin  hybridoma  cells.
Reduced  ERG  responses  from
recoverin-immunized  LPR  mice  and
balb/cJ  mice  injected  with  recoverin
hybridoma  cells  was  observed  under
dark-(scotopic ERG; A, B) and light-
adapted  (photopic  ERG;  A,  C)
conditions. Intensity-response curves of
the amplitude of flash b-wave, a-wave
from the dark-adapted ERG was shown
in B, and b-wave amplitudes from the
photopic ERG are depicted in C. The x-
axes indicate stimulus intensity (log cd-
s/m2).  The  y-axes  indicate  amplitude
(µV).  Student  t-test  showed  multiple
significant  differences  between
experimental  groups  compared  to
control values (see Table 1).
TABLE 1. STATISTICAL ANALYSIS OF ELECTRORETINOGRAM (ERG) RESPONSES IN RECOVERIN-IMMUNIZED B6.MRL-FALLPR/J (LPR) MICE AND BALB/
C MICE INJECTED WITH RECOVERIN HYBRIDOMA CELLS COMPARED TO CONTROL MICE VALUES.
ERG Parameters Recoverin-immunized LPR mice versus
control LPR mice
Balb/c anti-recoverin hybridoma mice versus
control balb/c mice
Rod-isolated b-wave p<0.007 p<0.001
Dark Max a-wave p<0.002 p<0.024
Dark Max b-wave p<0.003 p<0.001
Photopic b-wave p<0.002 p<0.001
          n=6 for each group.
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1941Figure 4. Histology changes. Retinal histology showed swollen cell bodies in the inner nuclear layer in recoverin-immunized B6.MRL-
Fallpr/J (LPR) mice, greater than the mild changes observed in the controls. Photoreceptor and outer nuclear layer waves were observed in the
retina of balb/cJ mice injected with recoverin hybridoma cells. Migrating cells between the inner nuclear layer (INL) and ganglion cell layer
(GCL) were also observed in these two mouse models. No change was observed in recoverin-immunized C57BL/6J mice. Abbreviations:
ONL is the outer nuclear layer; RPE is retinal pigment epithelium. Scale bar equal to 50 µm.
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1942deposits  was  remarkably  increased  in  the  RPE  layer  in
recoverin monoclonal antibody producing hybridoma cells
injected into balb/cJ mice compared to control mice; scattered
C3 deposits in the INL and GCL were also seen. (Figure 6).
Figure 5. Immunohistogic identification of retinal changes in recoverin-immunized B6.MRL-Fallpr/J (LPR) mice and balb/cJ mice injected
with recoverin hybridoma cells. Glial fibrillary acidic protein (GFAP) staining detected a marked increase of Muller cell reactive gliosis in
recoverin-immunized LPR mice and balb/cJ mice injected with recoverin hybridoma cells, which indicated retinal degeneration. Rhodopsin
and S-opsin expression were not altered in these groups, while bipolar cells (protein kinase alpha [PKC-α]) were decreased in both test groups.
There is no change in amacrine cells (calretinin) in these two mouse models, however the inner plexiform layer were reduced. Cell nuclei
were stained with 4',6-diamidino-2-phenylindole (DAPI; blue). Abbreviations: GCL represents ganglion cell layer; IPL represents inner
plexiform layer; INL represents Inner nuclear layer; ONL represents outer nuclear layer; RPE represents retinal pigment epithelium. Scale
bar equal to 50 µm.
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1943The migrating cells between the INL and GCL were CD3+
cells (Figure 6), and CD68+ cells were found in the RPE and
OPL of the retinas of Balb/c mice injected with recoverin
hybridoma cells (Figure 6).
Flow cytometry analysis of CD 68 (macrophage marker)
showed increased levels of CD68 positive cells (0.07%) in the
retinas  of  recoverin-immunized  LPR  mice  compared  to
control LPR mice (0.03%) (Figure 7). CD3 positive cells
increased (0.1%) in the retinas of recoverin-immunized LPR
Figure 6. Inflammatory changes in recoverin-immunized B6.MRL-Fallpr/J (LPR) mice and hybridoma balb/cJ mice. Increase of C1q and C3
deposition and infiltration of CD3+ and CD68+ cells in the retina of recoverin-immunized LPR mice and Balb/c mice injected with recoverin
hybridoma cells. No C1q deposition and C3 deposition in only retinal pigment epithelium (RPE) was observed in control LPR mice, while
they were enhanced in the RPE, inner nuclear layer (INL), and ganglion cell layer (GCL) of recoverin-immunized LPR mice retina. No C1q
or C3 deposition in RPE was observed in control Balb/c mice, while some C1q deposition was observed in the RPE, INL and GCL of the
retina of Balb/c mice injected with recoverin hybridoma cells, and a marked increase of C3 deposit on RPE and INL was observed. CD3+
cells were observed between the INL and GCL layers, and the migrating cells between INL and GCL were CD3+ cells. While CD68+ cells
were found in inner plexiform layer (IPL) and outer plexiform layer (OPL) in recoverin-immunized LPR mice retina, they were found in RPE
and OPL in Balb/c mice injected with recoverin hybridoma cells. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; blue).
Abbreviations: ONL, outer nuclear layer. Scale equal to 50 µm.
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1944mice compared to those of control LPR mice (0.02%). There
were no Ly6G positive cells, CD8 positive cells, or CD19
positive cells observed in either group.
DISCUSSION
Although AIR has been identified for over 15 years, an animal
model of this disease has not been available. Animal models,
and particularly mice with identical or very similar hereditary
disorders to man, have proven to be a powerful investigative
tool for understanding cellular, molecular, and degenerative
mechanisms  in  retinal  degeneration.  With  these  two  AIR
models it will be possible to provide new information about
the  pathophysiology  of  AIR,  specifically  looking  at
inflammatory mechanisms in the retina and testing different
putative pathologic retinal antigens known to be associated
with AIR. In this study, we described two mouse models with
immunologically  induced  retinopathy  associated  with
elevated recoverin antibodies; both models had attenuated
Figure 7. Retinal infiltrate-cell analysis
by  flow  cytometry.  CD68  and  CD3
positive  cells  were  increased  in
recoverin-immunized  LPR  mice
compared with control B6.MRL-Fallpr/
J (LPR), While no Ly6G positive cells
and CD19 positive cells were found in
both.
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1945scotopic and photopic ERGs, retinal thinning, accelerated C1q
and C3 deposits in the retinas, enhanced expression of GFAP
staining  identifying  a  reactive  gliosis,  and  infiltration  of
inflammatory cells, including macrophages and neutrophils.
Sixty-five percent of patients with AIR have a family
history  of  other  autoimmune  disorders  (e.g.,  rheumatoid
arthritis,  lupus,  thyroid  disease,  asthma)  and  having  an
autoimmune genetic background seems to make some patients
more susceptible to AIR [9]. The recoverin-immunized LPR
mice  showed  moderate  retinal  degeneration  that  was  not
found in the recoverin-immunized C57BL/6J mice (with no
autoimmune genetic background), similar to the pattern seen
in human AIR. Here, we only tested one retinal antigen to
stimulate antibody formation, while AIR patients normally
have multiple immunoreactive bands from circulating anti-
retinal antibodies on western blot testing. Identification of the
underlying antigenic proteins in AIR has been slow, and only
a few of the many antibodies found in AIR patients have been
proven  to  cause  retinal  damage  or  degeneration.  Most
immunoreactive bands (i.e., antibodies) from AIR patients
have not been investigated and their antigenic stimuli have yet
to be identified.
Recoverin has been proven to be a cause of AIR [3,10,
12,13]. A rat model system has been established to elucidate
the  contribution  of  recoverin  autoantibodies  to  the
development of retinopathy [13]. The injection of recoverin
has led to the induction of uveitis and retinal degeneration. In
a guinea pig model, animals were sensitized with small cell
lung  cancer  cell  lines  that  induced  production  of  anti-
recoverin  autoantibodies  in  the  animals  and  caused
retinopathy [27]. In an experimental BALB/c mouse model,
Maeda et al. induced specific cytotoxic T lymphocytes in
response to the peptide R64 (AYQHVFRSF) and observed a
tumor-preventive effect; however, this peptide also induced
the generation of antibodies and retinal degeneration [28]. Our
two mouse models have elevated circulating anti-recoverin
antibodies,  which  is  a  feature  observed  in  AIR  patients,
especially  CAR  patients.  In  other  studies,  anti-recoverin
autoantibodies induced apoptosis in photoreceptor and bipolar
cells,  leading  to  retinal  degeneration  [29,30].  We  did  not
observe apoptotic cells in these two models (data not shown),
but we only looked at one time point after the disease was
clearly present on the ERG. Serial Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and autophagy
studies will be needed in the future to further investigate this
issue. It is unclear why the blood-retinal barrier does not
prevent autoantibodies from penetrating into the retina, but
leukostasis  or  leukocyte  deposits  (focal  vascular  staining
[31]) on retinal vessel walls seen in AIR patients may damage
the tight junctions and allow immunoglobulin diffusion [31,
32].
One of the more important findings of this study was the
striking reactive retinal gliosis and infiltration by leukocytes
found  in  both  models.  Differential  changes  in  the  GFAP
expression  in  Mueller  glial  cells  is  the  most  sensitive
nonspecific response to retinal diseases and injuries and has
been used as a universal early cellular marker for retinal injury
[33].  The  finding  of  inflammatory  cells  on  retinal
histopathology and flow cytometry in our two mouse models
is consistent with recent case reports of AIR in systemic lupus
erythematosus.  Macrophages  were  seen  in  the  retina,
particularly  in  areas  of  photoreceptor  degeneration  [34].
Activation  of  infiltrating  macrophages  and  granulocytes
causes destruction of the retina by the release of reactive
oxygen species, including nitric oxide (NO) and superoxide
[35]. Humans with AIR do not have cells or flare in the
anterior  chamber  and  seldom  show  obvious  clinical
infiltration of the retina, although cystoid edema and retinal
wrinkling are commonly found [4]. White retinal patches are
seldom a feature in AIR. The new finding of a gliotic cellular
response  and  infiltration  of  retinas  by  inflammatory  cells
without  uveitis  is  important  and  is  likely  to  bear  on  the
pathologic degenerative mechanisms seen in AIR.
The complement system is involved in antigen-specific
immune  responses,  with  an  identified  role  in  antigen
processing  and  presentation,  T-cell  proliferation  and
differentiation,  and  B-cell  activation  [36].  Complement
activation products such as C3 have been shown to be present
in the eyes of patients with autoimmune uveitis [24] and in
drusen  in  patients  with  age-related  macular  degeneration
[25].  Our  two  mouse  models  show  elevated  C1q  and  C3
deposition in the RPE and INL of retinas. The complement
components  may  enhance  the  damage  initiated  by  the
pathogenic process. These preliminary results suggest further
investigation  is  needed  to  determine  the  role  of  the
complement system in AIR.
Conclusion: Two successful mouse models for AIR were
generated  by  our  experimental  approaches,  both  using
alternate  methods  of  producing  anti-recoverin  antibodies.
These models not only will be important for understanding the
pathogenesis and mechanisms involved in human AIR, but
will  also  be  valuable  for  testing  potential  therapies.  The
pathologic changes in anti-recoverin antibodies were not as
severe as we had expected, which may suggest that a mixture
of retinal antibodies may be the cause of the varying clinical
severity seen in AIR patients who typically have multiple
ARAs.
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